00000nam 2200000za 4500 9.849043 CaOODSP 20221107153825 cr ||||||||||| 171219s2017 onca| #o f000 0 eng d CaOODSP eng n-cn--- H82-30/2017E-PDF PMPRB guidelines scoping paper [electronic resource] : high level overview of potential new framework : CGI consultation phase. PMPRB potential new guidelines high level overview of potential new framework - CGI consultation phase [Ottawa] : Patented Medicine Prices Review Board, [2017] 9 p. : col. ill. Cover title. "This consultation period is 6 weeks, running from May 16, 2017 to June 28, 2017"--p. 5. Issued also in French under title: Protéger les Canadiens des prix excessifs des médicaments : consultation sur les modificaations proposées au Règlement sur les médicaments brevetés. Includes bibliographical references. "This scoping paper is intended to be read in conjunction with proposed amendments to the Patented Medicines Regulations (“Regulations”), and accompanying Regulatory Impact Analysis Statement (RIAS), which were pre-published in the December 2nd, 2017 issue of the Canada Gazette, Part I. Its purpose is to provide stakeholders and interested members of the public with an outline of the PMPRB’s preliminary thoughts on how best to operationalize the proposed changes to the Regulations, through non-binding Guidelines as contemplated by s.96 of the Patent Act, within the context of the existing and proposed legislation and the PMPRB’s ongoing efforts at reform"--p. 3 Introd. gccst Drugs gccst Price regulation gccst Consultations Canada. Patented Medicine Prices Review Board. Document d'orientation sur les lignes directrices du CEPMB (CaOODSP)9.849045 PDF 446 KB https://publications.gc.ca/collections/collection_2017/cepmb-pmprb/H82-30-2017-eng.pdf